Fulminant hepatic failure is the end result of many different acute damage to the liver. In the present study we compared the clinical to the experimental experience and we postulated the usage of Vascular Endothelial Growth Factor in the clinical arena as a potential treatment in alternative to liver transplantation.Twelve patient diagnosed with fulminat hepatic failure have been enclosed in the present study. Each patient underwent trans-jugular liver biopsy in order to assess the degree of liver necrosis as well as the following biochemical investigation: AST ALT, Total Bilirubin, _gt, alkaline phosphatase, prothrombin time.Twenty-five percent of those patients required support in the Intensive Care Unit without need for transplantation. Forty-one percent of those patients underwent liver transplantation, and 36% of them died before the liver become available. These results were compared with an experiment, previously performed by our group, where 260 rats were poisoned with CCl4 and subsequently treated with Vascula Endothelial Growth Factor (VEGF).The rate of the hepatic regeneration has been found to be critical in the prognosis of patients diagnosed with fulminant hepatic failure.